Latest Manufacturing Strategy News

AdAlta Limited has aligned its AdCella manufacturing strategy with new US FDA guidelines, made a significant milestone payment to Shanghai Cell Therapy Group, and secured an additional R&D tax rebate, marking key progress in its cellular immunotherapy pipeline.

Fluence Corporation reported a robust 72.9% revenue increase year-to-date Q3 2025, fueled by the Ivory Coast Addendum project, while maintaining its full-year guidance despite some margin pressures.

Lithium Energy Limited is progressing exploration and development across multiple battery mineral projects following the sale of its flagship Solaroz Lithium Project, while working to meet ASX reinstatement conditions.

Trajan Holdings delivered solid FY2025 results with revenue up 7.4% to $166.5 million and improved profitability despite transient costs and a biotech syringe loss. The company refinanced debt and set an optimistic FY2026 guidance range.

Fluence Corporation reported a robust 64.7% revenue increase in the first half of 2025, driven by strong project execution in Ivory Coast and growth in key business units. Despite tariff uncertainties and a cautious China outlook, the company maintains its full-year guidance and eyes further backlog expansion.

Argent BioPharma reports significant operational savings through manufacturing outsourcing, encouraging Phase IIb results for CimetrA®, and key regulatory approvals for cannabinoid therapies in Germany.

Fluence Corporation reported a robust Q1 2025 with revenue surging 64.5% year-over-year, driven by the Ivory Coast Addendum project, while EBITDA turned positive for the first time in over a year. The company maintains its full-year guidance despite tariff uncertainties.

Titomic Limited has entered a strategic teaming agreement with REPKON USA to jointly develop and apply its kinetic fusion cold spray technology for advanced defense manufacturing, focusing on repairs and performance enhancements of critical military assets.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.

PWR Holdings' North American arm, C&R Racing Inc., has landed a $8.9 million AUD order to supply advanced cooling systems for a US government aerospace project, marking a pivotal milestone in its defence sector expansion.